NurExone Biologic Inc.

NurExone Biologic Inc.

NRXBF - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$36.15M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
NurExone Biologic Inc.NurExone Biologic Inc.-4.3--498%--

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$36.15 Million
Enterprise Value$35.20 Million
Earnings per Share$-
Beta0.39
Outstanding Shares-

Return

Return on Equity-498.34%ROE
Return on Assets-240.99%
Return on Invested Capital-378.67%

Valuation & Multiples

P/E Ratio-4.28P/E Ratio
PEG48.5PEG
Price to Sales-Price to Sales
Price to Book Ratio-Price to Book Ratio
Enterprise Value to Revenue-
Enterprise Value to EBIT-5.6
Enterprise Value to Net Income-6
Total Debt to Enterprise0
Debt to Equity0.04Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
August 31, 2026
EPS
-$0.02
Est. -$0.02
Revenue Estimate
-
Consensus analyst estimate

Next Earnings Call

Expected Date
November 25, 2026
EPS Estimate
-$0.01
Consensus analyst estimate
Revenue Estimate
-
Consensus analyst estimate

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About NurExone Biologic Inc.

16 employees
CEO: Lior Shaltiel

NurExone Biologic Inc., a pharmaceutical technology company, develops a platform for biologically guided exosome-based therapies for the treatment of central nervous system injuries. Its lead product, ExoPTEN, has demonstrated strong pre...